<DOC>
	<DOC>NCT01088659</DOC>
	<brief_summary>This randomized, single blind study will compare the antiviral effect of Pegasys (pegylated interferon alfa-2a) plus placebo versus Pegasys plus tenofovir in patients with chronic hepatitis D. Patients will be randomized to receive 96 weeks of therapy with Pegasys (180 micrograms sc weekly) plus either placebo (orally daily) or tenofovir (245mg orally daily). Anticipated time on study treatment is 2+ years, target sample size is &lt;50.</brief_summary>
	<brief_title>A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<mesh_term>Hepatitis D, Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>adult patients, &gt;/=18 years of age chronic hepatitis D positive for HBsAg &gt;/=6 months, for antiHDV &gt;/=3 months and for HDVRNA at screening negative pregnancy test; fertile males and women of childbearing age should use two reliable forms of contraception throughout study antiviral therapy for chronic hepatitis D within the previous 6 months previous therapy with pegylated interferon alfa treatment with conventional interferon alfa for &gt;12 months hepatitis A or C, or HIV infection decompensated liver disease (Childs BC) history or evidence of medical condition associated with chronic liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>